Abstract
Ocular allergy and uveitis are varied groups of inflammatory eye disorders characterized by complex and as yet ill-defined pathogeneses. Alpha-1 antitrypsin (AAT) is the archetype of the serine protease inhibitor supergene family. AAT deficiency is one of many factors that may be involved in abnormalities such as liver and lung disease, inflammatory joint diseases, and inflammatory eye diseases. In the present review, the role played by AAT in ocular inflammation is analyzed, particularly in vernal keratoconjunctivitis (VKC) and uveitis. Tear trypsin inhibitory capacity was shown to be reduced in VKC patients. In uveitis patients, a significant difference in AAT phenotypes was found compared to normal subjects. We propose that a reduced inhibitory capacity of ATT and AAT might facilitate or prolong different types of ocular inflammation.
Keywords: Ocular allergy, uveitis, alpha-1-antitrypsin deficiency, vernal keratoconjunctivitis, HLA-B27 typing.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis
Volume: 9 Issue: 4
Author(s): Andrea Leonardi, Francesca Urban and Massimo Bortolotti
Affiliation:
Keywords: Ocular allergy, uveitis, alpha-1-antitrypsin deficiency, vernal keratoconjunctivitis, HLA-B27 typing.
Abstract: Ocular allergy and uveitis are varied groups of inflammatory eye disorders characterized by complex and as yet ill-defined pathogeneses. Alpha-1 antitrypsin (AAT) is the archetype of the serine protease inhibitor supergene family. AAT deficiency is one of many factors that may be involved in abnormalities such as liver and lung disease, inflammatory joint diseases, and inflammatory eye diseases. In the present review, the role played by AAT in ocular inflammation is analyzed, particularly in vernal keratoconjunctivitis (VKC) and uveitis. Tear trypsin inhibitory capacity was shown to be reduced in VKC patients. In uveitis patients, a significant difference in AAT phenotypes was found compared to normal subjects. We propose that a reduced inhibitory capacity of ATT and AAT might facilitate or prolong different types of ocular inflammation.
Export Options
About this article
Cite this article as:
Leonardi Andrea, Urban Francesca and Bortolotti Massimo, Role of Alpha-1 Antitrypsin (AAT) in Ocular Allergy and Uveitis, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2010; 9 (4) . https://dx.doi.org/10.2174/1871523011009040304
DOI https://dx.doi.org/10.2174/1871523011009040304 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-Inflammatory Drugs and Herbs with Special Emphasis on Herbal Medicines for Countering Inflammatory Diseases and Disorders - A Review
Recent Patents on Inflammation & Allergy Drug Discovery Genetic Engineering of Allergens for Immunotherapy
Inflammation & Allergy - Drug Targets (Discontinued) The Phage Display Technique: Advantages and Recent Patents
Recent Patents on DNA & Gene Sequences Chronic Urticaria: An Overview of Treatment and Recent Patents
Recent Patents on Inflammation & Allergy Drug Discovery Adverse Cutaneous Reactions of Systemic Antihistamines
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Dipeptidyl Peptidase IV Inhibitors: A New Paradigm in Type 2 Diabetes Treatment
Current Drug Targets Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease
Current Pharmaceutical Biotechnology Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Gender Differences in Response to Therapy for Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine A New Binding Site Involving the C-terminal Domain to Design Specific Inhibitors of PepX
Protein & Peptide Letters Inhibition of Zinc Metallopeptidases in Cardiovascular Disease - From Unity to Trinity, or Duality?
Current Pharmaceutical Design Structure Function Analysis of Serpin Super-Family: "A Computational Approach"
Protein & Peptide Letters Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Editorial (Hot Topic: Inflammation, Coagulation, Vascular Permeability and Thrombosis)
Current Vascular Pharmacology Current and Future Chemotherapy for Chagas Disease
Current Medicinal Chemistry Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety Drugs in Pediatric Ischemic Stroke
Current Drug Targets Cross-Reactivity in Cell-Mediated and IgE-Mediated Hypersensitivity to Glucocorticoids
Current Pharmaceutical Design